Qubis has backed Causeway's bid to create a nanochip-powered sensor that would help prevent ineffective antibiotic prescriptions.
Causeway Sensors, a UK-based counter-antibiotic resistance technology spinout from Queen’s University Belfast (QUB), has secured £1.2m ($1.7m) from investors including Qubis, QUB’s commercialisation arm, the Irish Independent reported yesterday.
Bank of Ireland Kernel Capital Growth Fund, a venture capital fund backed by financial services firm Bank of Ireland, led the round, which also featured unnamed private investors.
Founded in 2013, Causeway is creating a nanochip-powered sensor to classify infections as bacterial or viral in real time.
The technology is expected…
